Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
201lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
6 lessons
9mPeptidesIntermediate
Retatrutide and Chronic Kidney Disease: What the 2026 Meta-Analysis Adds
Retatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?
8mResearchAdvanced
MOTS-c and Mitochondrial Metabolism: What the 2026 Human Trial Is Testing
MOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.
7mResearchAdvanced
Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows
Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
9mResearchAdvanced
GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
9mPeptidesIntermediate
MOTS-c Enters Phase 2a Human Trial for Prediabetes: What the Research Shows
MOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
10mResearchAdvanced
Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows
TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
Also available at /blog for legacy links.